Skip to main content
. 2012 May 17;18(7):566–572. doi: 10.1111/j.1755-5949.2012.00321.x

Figure 3.

Figure 3

Trends in CBZ efficacy in carriers of various genotypes. The Pearson X3 was used to analyze the differences between carriers of the AA genotypes and carriers of the AG+GG genotypes with respect to the level of efficacy. The proportion of patients with seizure free (SF) among AA genotype carriers was significantly higher than that among AA+GG genotype carriers. Non‐SF indicated the combination of 75 %‐SF effecacy + 50–75% efficacy + < 50 % efficacy. *P<0.05